摘要
目的探讨卡泊芬净和米卡芬净在造血干细胞移植(HSCT)患者中的应用疗效,评价药物利用。方法通过收集和整理2010年8月-2011年7月医院内现有的棘白菌素类抗真菌药物在HSCT患者中的应用资料,对其进行回顾性分析,评价卡泊芬净和米卡芬净在HSCT患者中的疗效、不良反应及药物利用情况。结果应用卡泊芬净患者31例和应用米卡芬净患者49例,2组患者在年龄、性别、疾病种类、移植类型和用药时间上差异均无统计学意义;2组药物的有效率分别为68.4%和83.7%,差异也无统计学意义;2组不良反应发生率差异有统计学意义(P<0.05);卡泊芬净(DUI=1.050)和米卡芬净(DUI=0.983)使用基本合理,卡泊芬净的日用药金额为2042.6元,米卡芬净的日用药金额为1290.4元。结论 2种棘白菌素类药物在HSCT患者中疗效相当,但不良反应发生率却是卡泊芬净组高于米卡芬净组;二者的DUI≤1.0,为合理用药,卡泊芬净日用药金额是米卡芬净的1.6倍,由此提示二者在疗效和不良反应相当的情况下,米卡芬净从经济学角度上更具有优势。
OBJECTIVE To investigate the efficacy of caspofungin and micafungin in patients undergoing hematopoietic stem cell transplantation.METHODS The clinical data of HSCT patients received caspofungin and micafungin from Aug.2010 to Jul.2011 were collected.A retrospective analysis was employed to evaluate the efficacy,adverse reactions and utility of caspofungin and micafungin in HSCT patients.RESULTS Totally 31 patients received caspafungin and 49 patients received micafungin were enrolled.There were no statistical difference between the two groups in age,gender,the underlying disease,the type of transplantation and the time of administration.The effective rates of caspofungin and micafungin in the two groups were 68.4% and 83.7% respectively,with no statistical difference;there was statistical difference between the two groups in the incidence of adverse reactions（P〈0.05）.The DUIs of caspofungin and micafungin were 1.050 and 0.983,respectively.The DDC of caspofungin was 2042.6 yuan,and micafungin 1290.4 yuan.CONCLUSION The efficacy of the two types of echinocandin drugs is similar in HSCT patients,but the incidence of adverse reactions in caspofungin group is higher than micafungin.Both DUIs are less or close to 1.0,which are considered as reasonable use.DDC of caspofungin is 1.6 times higher than that of micafungin,suggesting micafungin is superior to micafungin on economical perspective while efficacy and adverse reactions are comparable.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2012年第2期380-382,共3页
Chinese Journal of Nosocomiology
基金
国家自然基金资助(30972523)
